RS102895 is primarily utilized in research settings as a selective antagonist for the chemokine receptor CCR2. This receptor plays a significant role in mediating inflammatory responses by recruiting immune cells to sites of inflammation. By inhibiting CCR2, RS102895 helps in studying the pathways and mechanisms involved in various inflammatory diseases, such as rheumatoid arthritis, atherosclerosis, and multiple sclerosis. It is also used in preclinical studies to explore potential therapeutic strategies for conditions where CCR2 signaling is implicated, including chronic pain and neuroinflammatory disorders. Additionally, RS102895 aids in understanding the role of CCR2 in tumor microenvironment modulation, providing insights into cancer progression and metastasis. Its application is crucial for developing targeted therapies that can modulate immune responses effectively.